BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 1569445)

  • 21. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
    J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential cisplatin/cyclophosphamide chemotherapy and abdominopelvic radiotherapy in the management of advanced ovarian cancer.
    Green JA; Warenius HM; Errington RD; Myint S; Spearing G; Slater AJ
    Br J Cancer; 1988 Nov; 58(5):635-9. PubMed ID: 3219276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin, epirubicin and cyclophosphamide (PEC) in the treatment of advanced ovarian cancer.
    Massacesi C; Bascioni R; Cellerino R; Scartozzi M; Bracci R; Alessandroni P; Antognoli S; Ciavattini A; De Nictolis M; Piga A
    J Exp Clin Cancer Res; 2000 Mar; 19(1):13-6. PubMed ID: 10840930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
    Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
    J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
    Hakes TB; Chalas E; Hoskins WJ; Jones WB; Markman M; Rubin SC; Chapman D; Almadrones L; Lewis JL
    Gynecol Oncol; 1992 Jun; 45(3):284-9. PubMed ID: 1612505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Homesley HD; Creasman WT; Berman ML; Ball H; Berek JS; Woodward J
    J Clin Oncol; 1995 Jul; 13(7):1589-99. PubMed ID: 7602348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary treatment of stage III ovarian carcinoma with sequential chemotherapy and whole abdominal radiation therapy.
    Reid GC; Roberts JA; Hopkins MP; Schoeppel SL; Perez-Tamayo C; Drescher C; Chamberlain D; Morley GW
    Gynecol Oncol; 1993 Jun; 49(3):333-8. PubMed ID: 8314535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
    Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
    J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
    Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
    Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity.
    Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G
    J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.